The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.
RSS Feed for InvestorBrandNetwork (IBN)June 4, 2026 — BOXABL announced that FGMC stockholders will vote June 9, 2026, on the proposed business combination that would take BOXABL public. FGMC is encouraging stockholders to vote in favor of the transaction and noted that public stockholders who do not redeem their shares will automatically become BOXABL stockholders upon closing.
June 4, 2026 — Tesla Inc. (NASDAQ: TSLA) is among the established leaders in utility-scale energy storage, a market drawing increased attention after Ford Motor Company’s announcement that it will invest approximately $2 billion to repurpose former EV battery manufacturing capacity for large-scale energy storage systems.
June 4, 2026 — Humanitas collaboration supports Regentis’ physician adoption strategy and broader commercial infrastructure across the European market. GelrinC targets a large orthopedic market that currently lacks an approved off-the-shelf regenerative cartilage repair solution.
June 3, 2026 — GlobalTech (OTC: GLTK) provided a shareholder update outlining its strategy to build a technology-centric holding company through disciplined capital allocation, operational execution and responsible innovation. The company highlighted its focus on combining established operating businesses with scalable technology platforms supported by its AI and Big Data Center of Excellence, while emphasizing commercialization, governance, compliance and long-term value creation.
June 3, 2026 — Earth Science Tech (OTC: ETST) announced that Chief Executive Officer and Chairman Giorgio R. Saumat will present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026, at the Bellagio Resort & Hotel in Las Vegas.
June 3, 2026 — Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization for international execution of Study SP-03-B101. The move follows recent regulatory approvals supporting study expansion and marks the transition of the Sapu003 program from an Australia-based clinical effort toward a broader multinational development strategy, including planned expansion into Europe.
June 3, 2026 — Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.
June 3, 2026 — Trident Digital Tech Holdings (NASDAQ: TDTH) announced the launch of TDTHAI, an artificial intelligence platform designed to support enterprise AI deployment, workflow automation, intelligent service delivery and digital transformation across the Asia-Pacific region. The company said the platform represents a key milestone in its evolution toward an AI-enabled digital infrastructure ecosystem spanning artificial intelligence, cybersecurity, digital identity, government technology, digital commerce and transaction-driven service platforms.
June 3, 2026 — LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced definitive agreements with accredited investors for a registered direct offering expected to generate approximately $16. 6 million in gross proceeds.
June 3, 2026 — TransCode Therapeutics (NASDAQ: RNAZ) announced additional results from its Phase 1a dose-escalation trial evaluating TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses.
June 3, 2026 — This article has been disseminated on behalf of MAX Power Mining Corp. and may include a paid advertisement.
June 3, 2026 — Rail Vision (NASDAQ: RVSN, FSE: C80) announced that its AI-powered ShuntingYard system has been integrated into Railserve’s newly introduced YardGUARD industrial railyard safety system, serving as a core technology within the WatchGUARD situational awareness and obstacle detection solution. The integration follows the companies’ recently announced memorandum of understanding and combines Rail Vision’s perception technology with communications and cloud-based monitoring capabilities to provide real-time visibility, obstacle detection, synchronized alerts and automatic braking support.
June 3, 2026 — Ferrari has always been known for building powerful sports cars with strong engines, exciting performance, and a unique driving experience. For many years, the Italian company has represented luxury, speed, and tradition.
June 3, 2026 — A new pill can reportedly double survival in early pancreatic cancer trials, raising cautious optimism about a disease that has long resisted treatment. Revolution Medicines’ daraxonrasib targets KRAS, a gene that supplies instructions for the development of the K-Ras protein which is essentially a switch for controlling cell division, growth, and death.
June 3, 2026 — BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines.
June 3, 2026 — The price of gold recorded some gains on Tuesday as yields on U. S.
June 3, 2026 — This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component used in the development of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor technology.
June 3, 2026 — Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial exploring how biotechnology companies are increasingly leveraging advanced drug-delivery technologies, nanotechnology platforms and artificial intelligence to enhance existing therapies and expand treatment opportunities. The article highlights Oncotelic’s Sapu003 program, Deciparticle(TM) platform and PDAOAI initiative as part of a broader industry trend toward scalable, multi-application biotechnology platforms capable of supporting oncology and rare disease programs.
June 3, 2026 — Earth Science Tech has evolved into a diversified healthcare holding company with operations spanning telemedicine, compounding pharmacies, clinical support services and healthcare fulfillment. In addition, the company has actively reduced its share count through a series of share repurchases documented in SEC filings and share structure records.
June 3, 2026 — VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu. Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus.